The approval of the first malaria treatment for newborns and young infants could lead to imminent widespread use in Africa, ...

Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...

The newly approved medication, Coartem Baby, is a combination of two antimalarials. It is a lower dose version of a tablet ...

Novartis has received approval in Switzerland for Coartem Baby, the first drug designed specifically to treat malaria in ...

A sweet cherry flavour, including in breast milk, and easily dissovleable drug is now approved for the treatment of malaria ...

Switzerland’s drug authority has granted approval for the first malaria medication specifically designed for infants and ...

Novartis said on Tuesday it had received approval in Switzerland for Coartem Baby, which it said was the first drug to treat ...

A new formulation of Novartis' antimalarial Coartem has become the first medicine to be approved for use in very young ...

The new drug, developed by Novartis and MMV, isn't a malaria vaccine, but can help treat babies with the disease.

The medicine, called Coartem Baby (also known as Riamet Baby), was approved by Switzerland’s health agency, Swissmedic.

In a historic move, Swissmedic has approved Coartem Baby, the first malaria treatment specifically for newborns and young ...